CleftGeneDB-Search

Gene: FGF9

Basic information

Tag	Content
Uniprot ID	P31371; A8K427; Q3SY32;
Entrez ID	2254
Genbank protein ID	AAI03979.1; BAA03572.1; AAI03980.1; AAT74624.1; EAX08316.1; BAF83481.1; AAH69692.1;
Genbank nucleotide ID	NM_002010.2
Ensembl protein ID	ENSP00000371790
Ensembl nucleotide ID	ENSG00000102678
Gene name	Fibroblast growth factor 9
Gene symbol	FGF9
Organism	Homo sapiens
NCBI taxa ID	9606
Cleft type
Developmental stage
Data sources	Homology search
Reference
Functional description	Plays an important role in the regulation of embryonic development, cell proliferation, cell differentiation and cell migration. May have a role in glial cell growth and differentiation during development, gliosis during repair and regeneration of brain tissue after damage, differentiation and survival of neuronal cells, and growth stimulation of glial tumors.
Sequence	MAPLGEVGNY FGVQDAVPFG NVPVLPVDSP VLLSDHLGQS EAGGLPRGPA VTDLDHLKGI 60 LRRRQLYCRT GFHLEIFPNG TIQGTRKDHS RFGILEFISI AVGLVSIRGV DSGLYLGMNE 120 KGELYGSEKL TQECVFREQF EENWYNTYSS NLYKHVDTGR RYYVALNKDG TPREGTRTKR 180 HQKFTHFLPR PVDPDKVPEL YKDILSQS 208

Abbreviation :
CLO : cleft lip only. CPO : cleft palate only. CLP : cleft lip and palate. CL/P : cleft lip with/without cleft palate.
For humans: CL/P, CLO, CPO, and CLP. For mice: CLO, CLP, and CPO.

Gene expression information

Gene expression in different tissues (GTEx V7)

Gene expression in different tissues (ENCODE)

Protein structural annotations

3D structure in PDB database

PDB ID
1G82
1IHK
5W59
1IHK

Protein disorder information

Orthologous information

Relation	Gene symbol	Entrez ID	UniProt ID	Cleft type	Developmental stage	Species	Evidence	Details
1:1 ortholog	FGF9	477340	J9P0B3			Canis lupus familiaris	Prediction	More>>
1:1 ortholog	FGF9	102169602	A0A452FF06			Capra hircus	Prediction	More>>
1:1 ortholog	FGF9	100050353	F7B6A2			Equus caballus	Prediction	More>>
1:1 ortholog	FGF9	2254	P31371			Homo sapiens	Prediction	More>>
1:1 ortholog	Fgf9	14180	P54130	CPO	E14.5, E16.5	Mus musculus	Publication	More>>
1:1 ortholog	FGF9	744731	H2Q7A1			Pan troglodytes	Prediction	More>>
1:1 ortholog	FGF9	396717	Q95L12			Sus scrofa	Prediction	More>>
1:1 ortholog	FGF9	100355861	G1SDY3			Oryctolagus cuniculus	Prediction	More>>
1:1 ortholog	Fgf9	25444	P36364			Rattus norvegicus	Prediction	More>>
1:1 ortholog	fgf20b	564770	Q2LJ24			Danio rerio	Prediction	More>>

Other genetic variants/mutations

ID	Variant	Type	Disease	Chromosome\Coordinate	Evidence
rs1254230677	p.Ala2Val	missense variant	-	NC_000013.11:g.21671917C>T	gnomAD
rs1480995733	p.Pro3Ser	missense variant	-	NC_000013.11:g.21671919C>T	TOPMed
rs1162900422	p.Glu6Asp	missense variant	-	NC_000013.11:g.21671930A>T	gnomAD
rs1234728690	p.Val7Ala	missense variant	-	NC_000013.11:g.21671932T>C	TOPMed
COSM3417425	p.Phe11Leu	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000013.11:g.21671945C>A	NCI-TCGA Cosmic
rs182718810	p.Val13Gly	missense variant	-	NC_000013.11:g.21671950T>G	1000Genomes,TOPMed,gnomAD
rs1430778022	p.Gln14Leu	missense variant	-	NC_000013.11:g.21671953A>T	gnomAD
rs145436564	p.Gln14His	missense variant	-	NC_000013.11:g.21671954G>C	1000Genomes,ESP,ExAC,TOPMed,gnomAD
COSM4046471	p.Gln14Arg	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000013.11:g.21671953A>G	NCI-TCGA Cosmic
NCI-TCGA novel	p.Asp15Asn	missense variant	-	NC_000013.11:g.21671955G>A	NCI-TCGA
rs997306736	p.Asp15His	missense variant	-	NC_000013.11:g.21671955G>C	TOPMed
rs774583506	p.Pro18Ser	missense variant	-	NC_000013.11:g.21671964C>T	ExAC,gnomAD
rs1212322820	p.Pro18Leu	missense variant	-	NC_000013.11:g.21671965C>T	gnomAD
rs767912297	p.Gly20Ala	missense variant	-	NC_000013.11:g.21671971G>C	ExAC,TOPMed,gnomAD
rs750656784	p.Leu25Val	missense variant	-	NC_000013.11:g.21671985T>G	ExAC,gnomAD
rs1277842781	p.Leu25Phe	missense variant	-	NC_000013.11:g.21671987G>C	gnomAD
rs759293888	p.Pro26Ser	missense variant	-	NC_000013.11:g.21671988C>T	ExAC,gnomAD
rs1412420802	p.Val27Leu	missense variant	-	NC_000013.11:g.21671991G>C	TOPMed
rs1187048373	p.Val27Ala	missense variant	-	NC_000013.11:g.21671992T>C	gnomAD
rs1238303573	p.Asp28Asn	missense variant	-	NC_000013.11:g.21671994G>A	gnomAD
NCI-TCGA novel	p.Ser29Asn	missense variant	-	NC_000013.11:g.21671998G>A	NCI-TCGA
rs576881958	p.Pro30Ser	missense variant	-	NC_000013.11:g.21672000C>T	1000Genomes,ExAC,TOPMed,gnomAD
NCI-TCGA novel	p.Val31GluPheSerTerUnk	frameshift	-	NC_000013.11:g.21672003_21672004insAGATA	NCI-TCGA
NCI-TCGA novel	p.Val31GlyPheSerTerUnk	frameshift	-	NC_000013.11:g.21672001_21672002insA	NCI-TCGA
rs376187337	p.Val31Leu	missense variant	-	NC_000013.11:g.21672003G>C	ESP,ExAC,TOPMed,gnomAD
rs570227715	p.Leu32Phe	missense variant	-	NC_000013.11:g.21672008G>C	1000Genomes,ExAC,gnomAD
rs1362488166	p.Ser34Asn	missense variant	-	NC_000013.11:g.21672013G>A	TOPMed
rs1373965286	p.Asp35Gly	missense variant	-	NC_000013.11:g.21672016A>G	gnomAD
NCI-TCGA novel	p.Leu37Met	missense variant	-	NC_000013.11:g.21672021C>A	NCI-TCGA
rs751136069	p.Gly38Arg	missense variant	-	NC_000013.11:g.21672024G>C	ExAC,gnomAD
rs150678654	p.Gly38Ala	missense variant	-	NC_000013.11:g.21672025G>C	ESP
rs756744215	p.Ser40Ala	missense variant	-	NC_000013.11:g.21672030T>G	ExAC,gnomAD
COSM3671250	p.Glu41Lys	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000013.11:g.21672033G>A	NCI-TCGA Cosmic
rs780871403	p.Ala42Gly	missense variant	-	NC_000013.11:g.21672037C>G	ExAC,gnomAD
NCI-TCGA novel	p.Leu45SerPheSerTerUnkUnk	frameshift	-	NC_000013.11:g.21672039G>-	NCI-TCGA
rs1301192320	p.Leu45Phe	missense variant	-	NC_000013.11:g.21672045C>T	TOPMed,gnomAD
rs780484804	p.Gly48Arg	missense variant	-	NC_000013.11:g.21672054G>A	ExAC,gnomAD
NCI-TCGA novel	p.Ala50CysPheSerTerUnkUnk	frameshift	-	NC_000013.11:g.21672059_21672060insT	NCI-TCGA
rs1346570038	p.Ala50Thr	missense variant	-	NC_000013.11:g.21672060G>A	gnomAD
COSM4826614	p.Ala50Pro	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000013.11:g.21672060G>C	NCI-TCGA Cosmic
rs774988398	p.Val51Ile	missense variant	-	NC_000013.11:g.21672063G>A	ExAC,gnomAD
rs772251822	p.Thr52Met	missense variant	-	NC_000013.11:g.21672067C>T	ExAC,gnomAD
rs755561237	p.Thr52Pro	missense variant	-	NC_000013.11:g.21672066A>C	ExAC,TOPMed,gnomAD
rs755561237	p.Thr52Ser	missense variant	-	NC_000013.11:g.21672066A>T	ExAC,TOPMed,gnomAD
rs760974340	p.Leu54Phe	missense variant	-	NC_000013.11:g.21672074G>T	ExAC,gnomAD
rs1213378667	p.His56Asp	missense variant	-	NC_000013.11:g.21672078C>G	TOPMed
NCI-TCGA novel	p.Leu61Phe	missense variant	-	NC_000013.11:g.21672093C>T	NCI-TCGA
NCI-TCGA novel	p.Arg62Trp	missense variant	-	NC_000013.11:g.21672096A>T	NCI-TCGA
rs1555223925	p.Arg62Gly	missense variant	Multiple synostoses syndrome 3 (syns3)	NC_000013.11:g.21672096A>G	-
RCV000513493	p.Arg62Gly	missense variant	Multiple synostoses syndrome 3 (SYNS3)	NC_000013.11:g.21672096A>G	ClinVar
NCI-TCGA novel	p.Arg63Gln	missense variant	-	NC_000013.11:g.21672100G>A	NCI-TCGA
rs762649405	p.Arg69Ser	missense variant	-	NC_000013.11:g.21672119G>C	ExAC,gnomAD
rs1258794930	p.Thr70Ser	missense variant	-	NC_000013.11:g.21672121C>G	TOPMed
COSM4046472	p.Thr70Ala	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000013.11:g.21672120A>G	NCI-TCGA Cosmic
COSM4879051	p.Leu74Ser	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000013.11:g.21672133T>C	NCI-TCGA Cosmic
rs751475837	p.Ile76Val	missense variant	-	NC_000013.11:g.21672138A>G	ExAC,gnomAD
rs756799366	p.Pro78Ala	missense variant	-	NC_000013.11:g.21672144C>G	ExAC,gnomAD
rs767042516	p.Pro78Leu	missense variant	-	NC_000013.11:g.21672145C>T	ExAC,gnomAD
rs1226739190	p.Asn79Asp	missense variant	-	NC_000013.11:g.21672147A>G	gnomAD
rs749883098	p.Asn79Ser	missense variant	-	NC_000013.11:g.21672148A>G	ExAC
rs755802170	p.Gly80Ser	missense variant	-	NC_000013.11:g.21672150G>A	ExAC,gnomAD
COSM4046473	p.Gly80Asp	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000013.11:g.21672151G>A	NCI-TCGA Cosmic
NCI-TCGA novel	p.Thr81Ser	missense variant	-	NC_000013.11:g.21672154C>G	NCI-TCGA
COSM6138968	p.Ile82Val	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000013.11:g.21672156A>G	NCI-TCGA Cosmic
NCI-TCGA novel	p.Gly84Glu	missense variant	-	NC_000013.11:g.21672163G>A	NCI-TCGA
rs1214948323	p.Arg86Gly	missense variant	-	NC_000013.11:g.21672168A>G	TOPMed
rs749722061	p.Asp88Ala	missense variant	-	NC_000013.11:g.21672175A>C	ExAC,gnomAD
rs779502534	p.Asp88His	missense variant	-	NC_000013.11:g.21672174G>C	ExAC
rs755277615	p.His89Pro	missense variant	-	NC_000013.11:g.21672178A>C	ExAC,gnomAD
rs1210713262	p.His89Asn	missense variant	-	NC_000013.11:g.21672177C>A	gnomAD
NCI-TCGA novel	p.Ser90Ile	missense variant	-	NC_000013.11:g.21672181G>T	NCI-TCGA
rs779607710	p.Arg91Gly	missense variant	-	NC_000013.11:g.21672183C>G	ExAC,gnomAD
NCI-TCGA novel	p.Gly93Asp	missense variant	-	NC_000013.11:g.21681042G>A	NCI-TCGA
rs12427696	p.Ile94Val	missense variant	-	NC_000013.11:g.21681044A>G	1000Genomes,ESP,ExAC,TOPMed,gnomAD
RCV000393748	p.Leu95Val	missense variant	Symphalangism-brachydactyly syndrome (SYNS1)	NC_000013.11:g.21681047C>G	ClinVar
rs776951218	p.Leu95Val	missense variant	-	NC_000013.11:g.21681047C>G	ExAC,TOPMed,gnomAD
NCI-TCGA novel	p.Glu96Asp	missense variant	-	NC_000013.11:g.21681052A>C	NCI-TCGA
rs121918322	p.Ser99Asn	missense variant	Multiple synostoses syndrome 3 (SYNS3)	NC_000013.11:g.21681060G>A	UniProt,dbSNP
VAR_063254	p.Ser99Asn	missense variant	Multiple synostoses syndrome 3 (SYNS3)	NC_000013.11:g.21681060G>A	UniProt
rs121918322	p.Ser99Asn	missense variant	Multiple synostoses syndrome 3 (syns3)	NC_000013.11:g.21681060G>A	-
RCV000009242	p.Ser99Asn	missense variant	Multiple synostoses syndrome 3 (SYNS3)	NC_000013.11:g.21681060G>A	ClinVar
rs1308480939	p.Ile100Val	missense variant	-	NC_000013.11:g.21681062A>G	gnomAD
rs1352104938	p.Ile100Met	missense variant	-	NC_000013.11:g.21681064A>G	gnomAD
NCI-TCGA novel	p.Ala101Thr	missense variant	-	NC_000013.11:g.21681065G>A	NCI-TCGA
COSM6074453	p.Ala101Glu	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000013.11:g.21681066C>A	NCI-TCGA Cosmic
COSM3467671	p.Gly103Ser	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000013.11:g.21681071G>A	NCI-TCGA Cosmic
NCI-TCGA novel	p.Leu104ProPheSerTerUnkUnk	frameshift	-	NC_000013.11:g.21681072_21681073insA	NCI-TCGA
rs753255725	p.Arg108Gln	missense variant	-	NC_000013.11:g.21681087G>A	gnomAD
COSM275167	p.Arg108Ter	stop gained	Variant assessed as Somatic; HIGH impact.	NC_000013.11:g.21681086C>T	NCI-TCGA Cosmic
rs774141078	p.Val110Met	missense variant	-	NC_000013.11:g.21681092G>A	ExAC,gnomAD
COSM3467672	p.Gly113Glu	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000013.11:g.21681102G>A	NCI-TCGA Cosmic
rs1245671881	p.Leu116Ile	missense variant	-	NC_000013.11:g.21681110C>A	gnomAD
COSM3467673	p.Gly117Trp	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000013.11:g.21681113G>T	NCI-TCGA Cosmic
NCI-TCGA novel	p.Lys121ArgPheSerTerUnkUnk	frameshift	-	NC_000013.11:g.21681125A>-	NCI-TCGA
rs773003683	p.Leu124Met	missense variant	-	NC_000013.11:g.21681134C>A	ExAC,TOPMed,gnomAD
rs765842747	p.Gly126Arg	missense variant	-	NC_000013.11:g.21681140G>C	ExAC,gnomAD
rs1198320298	p.Ser127Ala	missense variant	-	NC_000013.11:g.21681143T>G	gnomAD
COSM4878283	p.Ser127Thr	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000013.11:g.21681143T>A	NCI-TCGA Cosmic
rs1189091971	p.Glu128Lys	missense variant	-	NC_000013.11:g.21701190G>A	gnomAD
NCI-TCGA novel	p.Lys129AsnPheSerTerUnk	frameshift	-	NC_000013.11:g.21701191A>-	NCI-TCGA
rs1391997109	p.Leu130Pro	missense variant	-	NC_000013.11:g.21701197T>C	gnomAD
rs1379079857	p.Leu130Ile	missense variant	-	NC_000013.11:g.21701196C>A	TOPMed
rs267603777	p.Gln132Glu	missense variant	-	NC_000013.11:g.21701202C>G	ExAC,TOPMed
rs267603777	p.Gln132Ter	stop gained	-	NC_000013.11:g.21701202C>T	ExAC,TOPMed
NCI-TCGA novel	p.Glu133Gln	missense variant	-	NC_000013.11:g.21701205G>C	NCI-TCGA
rs200015821	p.Cys134Ser	missense variant	-	NC_000013.11:g.21701208T>A	ExAC,gnomAD
rs1466682170	p.Val135Ile	missense variant	-	NC_000013.11:g.21701211G>A	gnomAD
rs1338958021	p.Phe136Leu	missense variant	-	NC_000013.11:g.21701214T>C	gnomAD
rs759113908	p.Phe136Leu	missense variant	-	NC_000013.11:g.21701216C>G	ExAC,gnomAD
COSM945978	p.Arg137Ile	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000013.11:g.21701218G>T	NCI-TCGA Cosmic
rs765041263	p.Phe140Leu	missense variant	-	NC_000013.11:g.21701228C>A	ExAC,TOPMed,gnomAD
rs1010781871	p.Glu141Lys	missense variant	-	NC_000013.11:g.21701229G>A	TOPMed,gnomAD
COSM3417426	p.Glu142Ter	stop gained	Variant assessed as Somatic; HIGH impact.	NC_000013.11:g.21701232G>T	NCI-TCGA Cosmic
rs963305629	p.Thr147Met	missense variant	-	NC_000013.11:g.21701248C>T	TOPMed
rs751903634	p.Ser149Leu	missense variant	-	NC_000013.11:g.21701254C>T	ExAC,gnomAD
COSM1322936	p.Ser150Ter	stop gained	Variant assessed as Somatic; HIGH impact.	NC_000013.11:g.21701257C>A	NCI-TCGA Cosmic
rs750565955	p.Leu152Val	missense variant	-	NC_000013.11:g.21701262C>G	ExAC,gnomAD
rs143118647	p.His155Gln	missense variant	-	NC_000013.11:g.21701273C>G	ESP,ExAC,TOPMed,gnomAD
rs749546597	p.Val156Leu	missense variant	-	NC_000013.11:g.21701274G>T	ExAC,gnomAD
rs1208866316	p.Thr158Ser	missense variant	-	NC_000013.11:g.21701280A>T	gnomAD
rs1249806783	p.Gly159Arg	missense variant	-	NC_000013.11:g.21701283G>A	gnomAD
rs146697820	p.Arg161Pro	missense variant	-	NC_000013.11:g.21701290G>C	ESP,ExAC,TOPMed,gnomAD
rs146697820	p.Arg161Gln	missense variant	-	NC_000013.11:g.21701290G>A	ESP,ExAC,TOPMed,gnomAD
COSM469244	p.Arg161Ter	stop gained	Variant assessed as Somatic; HIGH impact.	NC_000013.11:g.21701289C>T	NCI-TCGA Cosmic
NCI-TCGA novel	p.Asn167Asp	missense variant	-	NC_000013.11:g.21701307A>G	NCI-TCGA
rs746751637	p.Asn167Ser	missense variant	-	NC_000013.11:g.21701308A>G	ExAC,gnomAD
rs746751637	p.Asn167Thr	missense variant	-	NC_000013.11:g.21701308A>C	ExAC,gnomAD
rs1304374985	p.Lys168Glu	missense variant	-	NC_000013.11:g.21701310A>G	TOPMed
rs1267713584	p.Thr171Ser	missense variant	-	NC_000013.11:g.21701320C>G	gnomAD
rs776618974	p.Pro172Ser	missense variant	-	NC_000013.11:g.21701322C>T	ExAC,TOPMed,gnomAD
rs371548027	p.Pro172Leu	missense variant	-	NC_000013.11:g.21701323C>T	ESP
COSM1706514	p.Glu174Lys	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000013.11:g.21701328G>A	NCI-TCGA Cosmic
rs1366332994	p.Gly175Ala	missense variant	-	NC_000013.11:g.21701332G>C	TOPMed
COSM136929	p.Gly175Glu	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000013.11:g.21701332G>A	NCI-TCGA Cosmic
rs550814848	p.Arg180Gln	missense variant	-	NC_000013.11:g.21701347G>A	1000Genomes,ExAC,gnomAD
rs763743837	p.Arg180Trp	missense variant	-	NC_000013.11:g.21701346C>T	ExAC,gnomAD
rs1424759069	p.His181Asn	missense variant	-	NC_000013.11:g.21701349C>A	TOPMed
NCI-TCGA novel	p.Gln182His	missense variant	-	NC_000013.11:g.21701354G>C	NCI-TCGA
rs762229622	p.Gln182Arg	missense variant	-	NC_000013.11:g.21701353A>G	ExAC,gnomAD
rs767964377	p.Phe184Leu	missense variant	-	NC_000013.11:g.21701360C>G	ExAC,TOPMed,gnomAD
NCI-TCGA novel	p.Phe187Leu	missense variant	-	NC_000013.11:g.21701367T>C	NCI-TCGA
COSM2265921	p.Leu188TyrPheSerTerUnkUnk	frameshift	Variant assessed as Somatic; HIGH impact.	NC_000013.11:g.21701366T>-	NCI-TCGA Cosmic
NCI-TCGA novel	p.Asp195His	missense variant	-	NC_000013.11:g.21701391G>C	NCI-TCGA
rs369272027	p.Asp195Asn	missense variant	-	NC_000013.11:g.21701391G>A	ESP,ExAC,TOPMed,gnomAD
rs755164853	p.Asp195Gly	missense variant	-	NC_000013.11:g.21701392A>G	ExAC,gnomAD
rs369272027	p.Asp195Tyr	missense variant	-	NC_000013.11:g.21701391G>T	ESP,ExAC,TOPMed,gnomAD
rs1357445252	p.Tyr201Cys	missense variant	-	NC_000013.11:g.21701410A>G	TOPMed
rs1220671836	p.Asp203Ala	missense variant	-	NC_000013.11:g.21701416A>C	gnomAD
rs1489320468	p.Ser206Gly	missense variant	-	NC_000013.11:g.21701424A>G	gnomAD
rs1283814283	p.Gln207Arg	missense variant	-	NC_000013.11:g.21701428A>G	TOPMed
COSM4962730	p.Ser208Arg	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000013.11:g.21701430A>C	NCI-TCGA Cosmic

Disease or phenotype associated information

Disease ID	Disease Name	Disease Type	Source
C0001418	Adenocarcinoma	group	BEFREE;CTD_human
C0003467	Anxiety	disease	BEFREE
C0003469	Anxiety Disorders	group	BEFREE
C0005967	Bone neoplasms	group	BEFREE
C0006118	Brain Neoplasms	group	BEFREE
C0006142	Malignant neoplasm of breast	disease	BEFREE
C0007102	Malignant tumor of colon	disease	BEFREE
C0007131	Non-Small Cell Lung Carcinoma	disease	BEFREE;CTD_human
C0007137	Squamous cell carcinoma	disease	BEFREE
C0008924	Cleft upper lip	disease	CTD_human
C0008925	Cleft Palate	disease	CTD_human
C0009402	Colorectal Carcinoma	disease	BEFREE
C0010278	Craniosynostosis	disease	BEFREE;GENOMICS_ENGLAND
C0011570	Mental Depression	disease	BEFREE
C0011581	Depressive disorder	disease	BEFREE
C0014175	Endometriosis	disease	BEFREE
C0014868	Esophagitis	disease	BEFREE
C0017636	Glioblastoma	disease	BEFREE
C0017638	Glioma	disease	BEFREE
C0018051	Gonadal Dysgenesis	disease	BEFREE;LHGDN
C0018777	Conductive hearing loss	disease	HPO
C0022665	Kidney Neoplasm	disease	BEFREE
C0024121	Lung Neoplasms	group	CTD_human
C0024623	Malignant neoplasm of stomach	disease	BEFREE
C0024624	Malignant neoplasm of upper lobe, bronchus or lung	disease	MGD
C0025286	Meningioma	disease	BEFREE
C0027627	Neoplasm Metastasis	phenotype	BEFREE
C0027651	Neoplasms	group	BEFREE
C0033578	Prostatic Neoplasms	group	LHGDN
C0033975	Psychotic Disorders	group	BEFREE
C0039093	Congenital abnormal Synostosis	disease	BEFREE
C0039743	Thanatophoric Dysplasia	disease	BEFREE
C0041408	Turner Syndrome	disease	BEFREE
C0149782	Squamous cell carcinoma of lung	disease	BEFREE
C0152013	Adenocarcinoma of lung (disorder)	disease	BEFREE
C0153491	Malignant neoplasm of middle lobe, bronchus or lung	disease	MGD
C0153492	Malignant neoplasm of lower lobe, bronchus or lung	disease	MGD
C0153493	Malignant neoplasm of other parts of bronchus or lung	disease	MGD
C0158465	Acquired cubitus valgus	phenotype	HPO
C0162298	Joint stiffness	phenotype	HPO
C0175700	Multiple synostosis syndrome	disease	BEFREE;ORPHANET
C0178874	Tumor Progression	phenotype	BEFREE
C0205641	Adenocarcinoma, Basal Cell	disease	CTD_human
C0205642	Adenocarcinoma, Oxyphilic	disease	CTD_human
C0205643	Carcinoma, Cribriform	disease	CTD_human
C0205644	Carcinoma, Granular Cell	disease	CTD_human
C0205645	Adenocarcinoma, Tubular	disease	CTD_human
C0206659	Embryonal Carcinoma	disease	BEFREE
C0221357	Brachydactyly	disease	HPO
C0242379	Malignant neoplasm of lung	disease	CTD_human
C0278701	Gastric Adenocarcinoma	disease	BEFREE
C0341106	Eosinophilic esophagitis	disease	BEFREE
C0342282	Multiple synostoses syndrome 1	disease	ORPHANET
C0345967	Malignant mesothelioma	disease	CTD_human
C0349204	Nonorganic psychosis	disease	BEFREE
C0376358	Malignant neoplasm of prostate	disease	BEFREE
C0426891	Broad thumbs	phenotype	HPO
C0432470	46, XY female	disease	BEFREE
C0476089	Endometrial Carcinoma	disease	BEFREE
C0525045	Mood Disorders	group	BEFREE
C0596263	Carcinogenesis	phenotype	BEFREE
C0600139	Prostate carcinoma	disease	BEFREE
C0678222	Breast Carcinoma	disease	BEFREE
C0686619	Secondary malignant neoplasm of lymph node	disease	BEFREE
C0699790	Colon Carcinoma	disease	BEFREE
C0699791	Stomach Carcinoma	disease	BEFREE
C1266144	Pleuropulmonary blastoma	disease	BEFREE;MGD
C1269683	Major Depressive Disorder	disease	BEFREE
C1384583	Congenital absence of germinal epithelium of testes	disease	BEFREE
C1569637	Adenocarcinoma, Endometrioid	disease	BEFREE
C1704272	Benign Prostatic Hyperplasia	disease	BEFREE
C1837218	Cleft palate, isolated	disease	CTD_human
C1840089	Limited interphalangeal movement	phenotype	HPO
C1843108	Short palm	phenotype	HPO
C1862095	Bilateral single transverse palmar creases	phenotype	HPO
C1862697	Metatarsal synostosis	phenotype	HPO
C1863360	Radiohumeral synostosis of elbow	phenotype	HPO
C1865037	Cone-shaped epiphysis	phenotype	HPO
C1868678	THANATOPHORIC DYSPLASIA, TYPE I (disorder)	disease	BEFREE
C2751826	Multiple Synostoses Syndrome 3	disease	CLINVAR;CTD_human;UNIPROT
C2930865	Ramer Ladda syndrome	disease	HPO
C3494358	Prodromal Symptoms	phenotype	BEFREE
C4021390	Symphalangism affecting the phalanges of the hand	phenotype	HPO
C4021398	Metacarpal synostosis	phenotype	HPO

Gene Ontology (GO)/biological pathways

GO:Molecular Function

GO ID	GO Term	Evidence
GO:0005104	fibroblast growth factor receptor binding	IEA
GO:0008083	growth factor activity	IEA
GO:0008201	heparin binding	IEA

GO:Biological Process

GO ID	GO Term	Evidence
GO:0000122	negative regulation of transcription by RNA polymerase II	IEA
GO:0000165	MAPK cascade	TAS
GO:0001525	angiogenesis	IEA
GO:0001649	osteoblast differentiation	IEA
GO:0001654	eye development	IEA
GO:0002053	positive regulation of mesenchymal cell proliferation	IEA
GO:0002062	chondrocyte differentiation	IEA
GO:0006606	protein import into nucleus	IEA
GO:0007165	signal transduction	TAS
GO:0007267	cell-cell signaling	IEA
GO:0008284	positive regulation of cell population proliferation	IDA
GO:0008543	fibroblast growth factor receptor signaling pathway	IGI
GO:0008543	fibroblast growth factor receptor signaling pathway	TAS
GO:0008584	male gonad development	IEP
GO:0010628	positive regulation of gene expression	IEA
GO:0021762	substantia nigra development	HEP
GO:0030178	negative regulation of Wnt signaling pathway	IEA
GO:0030238	male sex determination	IEA
GO:0030326	embryonic limb morphogenesis	IEA
GO:0030949	positive regulation of vascular endothelial growth factor receptor signaling pathway	IEA
GO:0032927	positive regulation of activin receptor signaling pathway	IEA
GO:0042472	inner ear morphogenesis	IEA
GO:0043410	positive regulation of MAPK cascade	IEA
GO:0045880	positive regulation of smoothened signaling pathway	IEA
GO:0048505	regulation of timing of cell differentiation	IEA
GO:0048566	embryonic digestive tract development	IEA
GO:0048706	embryonic skeletal system development	IEA
GO:0050679	positive regulation of epithelial cell proliferation	IEA
GO:0051781	positive regulation of cell division	IEA
GO:0051897	positive regulation of protein kinase B signaling	TAS
GO:0060045	positive regulation of cardiac muscle cell proliferation	IEA
GO:0060484	lung-associated mesenchyme development	IEA
GO:0090263	positive regulation of canonical Wnt signaling pathway	IEA
GO:1904707	positive regulation of vascular smooth muscle cell proliferation	ISS
GO:1904707	positive regulation of vascular smooth muscle cell proliferation	IGI
GO:1904754	positive regulation of vascular associated smooth muscle cell migration	ISS
GO:1905931	negative regulation of vascular smooth muscle cell differentiation involved in phenotypic switching	ISS

GO:Cellular Component

GO ID	GO Term	Evidence
GO:0005576	extracellular region	TAS
GO:0005604	basement membrane	IEA
GO:0005615	extracellular space	IDA
GO:0005737	cytoplasm	IEA

Reactome Pathway

Reactome ID	Reactome Term	Evidence
R-HSA-109704	PI3K Cascade	TAS
R-HSA-112399	IRS-mediated signalling	TAS
R-HSA-1226099	Signaling by FGFR in disease	TAS
R-HSA-1257604	PIP3 activates AKT signaling	TAS
R-HSA-1280215	Cytokine Signaling in Immune system	TAS
R-HSA-162582	Signal Transduction	TAS
R-HSA-1643685	Disease	TAS
R-HSA-168256	Immune System	TAS
R-HSA-1839122	Signaling by activated point mutants of FGFR1	TAS
R-HSA-1839124	FGFR1 mutant receptor activation	TAS
R-HSA-1839126	FGFR2 mutant receptor activation	TAS
R-HSA-1839130	Signaling by activated point mutants of FGFR3	TAS
R-HSA-190236	Signaling by FGFR	TAS
R-HSA-190239	FGFR3 ligand binding and activation	TAS
R-HSA-190241	FGFR2 ligand binding and activation	TAS
R-HSA-190242	FGFR1 ligand binding and activation	TAS
R-HSA-190322	FGFR4 ligand binding and activation	TAS
R-HSA-190371	FGFR3b ligand binding and activation	TAS
R-HSA-190372	FGFR3c ligand binding and activation	TAS
R-HSA-190373	FGFR1c ligand binding and activation	TAS
R-HSA-190375	FGFR2c ligand binding and activation	TAS
R-HSA-199418	Negative regulation of the PI3K/AKT network	TAS
R-HSA-2033514	FGFR3 mutant receptor activation	TAS
R-HSA-2033519	Activated point mutants of FGFR2	TAS
R-HSA-2219528	PI3K/AKT Signaling in Cancer	TAS
R-HSA-2219530	Constitutive Signaling by Aberrant PI3K in Cancer	TAS
R-HSA-2404192	Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)	TAS
R-HSA-2428924	IGF1R signaling cascade	TAS
R-HSA-2428928	IRS-related events triggered by IGF1R	TAS
R-HSA-5654219	Phospholipase C-mediated cascade: FGFR1	TAS
R-HSA-5654221	Phospholipase C-mediated cascade; FGFR2	TAS
R-HSA-5654227	Phospholipase C-mediated cascade; FGFR3	TAS
R-HSA-5654228	Phospholipase C-mediated cascade; FGFR4	TAS
R-HSA-5654687	Downstream signaling of activated FGFR1	TAS
R-HSA-5654688	SHC-mediated cascade:FGFR1	TAS
R-HSA-5654689	PI-3K cascade:FGFR1	TAS
R-HSA-5654693	FRS-mediated FGFR1 signaling	TAS
R-HSA-5654695	PI-3K cascade:FGFR2	TAS
R-HSA-5654696	Downstream signaling of activated FGFR2	TAS
R-HSA-5654699	SHC-mediated cascade:FGFR2	TAS
R-HSA-5654700	FRS-mediated FGFR2 signaling	TAS
R-HSA-5654704	SHC-mediated cascade:FGFR3	TAS
R-HSA-5654706	FRS-mediated FGFR3 signaling	TAS
R-HSA-5654708	Downstream signaling of activated FGFR3	TAS
R-HSA-5654710	PI-3K cascade:FGFR3	TAS
R-HSA-5654712	FRS-mediated FGFR4 signaling	TAS
R-HSA-5654716	Downstream signaling of activated FGFR4	TAS
R-HSA-5654719	SHC-mediated cascade:FGFR4	TAS
R-HSA-5654720	PI-3K cascade:FGFR4	TAS
R-HSA-5654726	Negative regulation of FGFR1 signaling	TAS
R-HSA-5654727	Negative regulation of FGFR2 signaling	TAS
R-HSA-5654732	Negative regulation of FGFR3 signaling	TAS
R-HSA-5654733	Negative regulation of FGFR4 signaling	TAS
R-HSA-5654736	Signaling by FGFR1	TAS
R-HSA-5654738	Signaling by FGFR2	TAS
R-HSA-5654741	Signaling by FGFR3	TAS
R-HSA-5654743	Signaling by FGFR4	TAS
R-HSA-5655253	Signaling by FGFR2 in disease	TAS
R-HSA-5655302	Signaling by FGFR1 in disease	TAS
R-HSA-5655332	Signaling by FGFR3 in disease	TAS
R-HSA-5663202	Diseases of signal transduction	TAS
R-HSA-5673001	RAF/MAP kinase cascade	TAS
R-HSA-5683057	MAPK family signaling cascades	TAS
R-HSA-5684996	MAPK1/MAPK3 signaling	TAS
R-HSA-6811558	PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling	TAS
R-HSA-74751	Insulin receptor signalling cascade	TAS
R-HSA-74752	Signaling by Insulin receptor	TAS
R-HSA-8853338	Signaling by FGFR3 point mutants in cancer	TAS
R-HSA-9006925	Intracellular signaling by second messengers	TAS
R-HSA-9006934	Signaling by Receptor Tyrosine Kinases	TAS
R-HSA-9607240	FLT3 Signaling	TAS

Drugs and compounds information

ID	Drug Name	Action	PubMed
C026486	1,2,5,6-dibenzanthracene	1,2,5,6-dibenzanthracene results in increased expression of FGF9 mRNA	19358281
C046760	15-acetyldeoxynivalenol	15-acetyldeoxynivalenol results in increased expression of FGF9 mRNA	23792671
D015655	1-Methyl-4-phenylpyridinium	1-Methyl-4-phenylpyridinium results in decreased expression of FGF9 mRNA	19476551
D015655	1-Methyl-4-phenylpyridinium	1-Methyl-4-phenylpyridinium results in decreased expression of FGF9 protein	19476551
D015655	1-Methyl-4-phenylpyridinium	Melatonin inhibits the reaction [1-Methyl-4-phenylpyridinium results in decreased expression of FGF9 mRNA]	19476551
D015655	1-Methyl-4-phenylpyridinium	Melatonin inhibits the reaction [1-Methyl-4-phenylpyridinium results in decreased expression of FGF9 protein]	19476551
D015655	1-Methyl-4-phenylpyridinium	FGF9 protein results in decreased susceptibility to 1-Methyl-4-phenylpyridinium	19476551
C093973	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Benzo(a)pyrene results in increased expression of FGF9 mRNA]	20464547
C093973	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Particulate Matter results in increased expression of FGF9 mRNA]	20464547
C038890	2,3,4,7,8-pentachlorodibenzofuran	2,3,4,7,8-pentachlorodibenzofuran results in increased expression of FGF9 mRNA	19358281
C006551	2-amino-2-methyl-1-propanol	2-amino-2-methyl-1-propanol results in decreased expression of FGF9 mRNA	25088246
C023035	3,4,5,3',4'-pentachlorobiphenyl	3,4,5,3',4'-pentachlorobiphenyl results in increased expression of FGF9 mRNA	19358281
C023035	3,4,5,3',4'-pentachlorobiphenyl	3,4,5,3',4'-pentachlorobiphenyl results in decreased expression of FGF9 mRNA	23196670
C090942	4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole	4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole inhibits the reaction [Benzo(a)pyrene results in increased expression of FGF9 mRNA]	20464547
C090942	4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole	4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole inhibits the reaction [Particulate Matter results in increased expression of FGF9 mRNA]	20464547
C459179	4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FGF9 mRNA	27188386
C459179	4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FGF9 mRNA	27188386
C459179	4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FGF9 mRNA	27188386
C459179	4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FGF9 mRNA	27188386
C459179	4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FGF9 mRNA	27188386
C459179	4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FGF9 mRNA	27188386
C459179	4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FGF9 mRNA	27188386
C459179	4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	[NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FGF9 mRNA	27188386
C459179	4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	[NOG protein co-treated with Vorinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FGF9 mRNA	27188386
D015123	7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide	7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide results in increased expression of FGF9 mRNA	20382639
D015124	8-Bromo Cyclic Adenosine Monophosphate	8-Bromo Cyclic Adenosine Monophosphate results in increased expression of FGF9 mRNA	22079614
D016604	Aflatoxin B1	Aflatoxin B1 results in decreased methylation of FGF9 gene	27153756
D019386	Alendronate	Alendronate affects the expression of FGF9 mRNA	16079270
D000643	Ammonium Chloride	Ammonium Chloride affects the expression of FGF9 mRNA	16483693
D000735	Androstenedione	FGF9 protein inhibits the reaction [IGF1 protein promotes the reaction [Bucladesine results in increased abundance of Androstenedione]]	22872763
D000735	Androstenedione	FGF9 protein inhibits the reaction [[LHB protein co-treated with IGF1 protein] results in increased abundance of Androstenedione]	22872763
D000735	Androstenedione	FGF9 protein inhibits the reaction [LHB protein results in increased abundance of Androstenedione]	22872763
D001151	Arsenic	Arsenic affects the methylation of FGF9 gene	25304211
C547126	AZM551248	AZM551248 results in decreased expression of FGF9 mRNA	22323515
D001397	Azoxymethane	[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of FGF9 mRNA	29950665
C487081	belinostat	belinostat results in decreased expression of FGF9 mRNA	26272509
C487081	belinostat	[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FGF9 mRNA	27188386
C030935	benz(a)anthracene	benz(a)anthracene results in increased expression of FGF9 mRNA	19358281
D001564	Benzo(a)pyrene	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Benzo(a)pyrene results in increased expression of FGF9 mRNA]	20464547
D001564	Benzo(a)pyrene	4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole inhibits the reaction [Benzo(a)pyrene results in increased expression of FGF9 mRNA]	20464547
D001564	Benzo(a)pyrene	Benzo(a)pyrene results in increased expression of FGF9 mRNA	16002475; 19358281; 20464547;
D001564	Benzo(a)pyrene	Benzo(a)pyrene results in increased expression of FGF9 protein	20464547
D001564	Benzo(a)pyrene	Benzo(a)pyrene results in increased expression of FGF9 mRNA	23735875
C006703	benzo(b)fluoranthene	benzo(b)fluoranthene results in increased expression of FGF9 mRNA	26377693
C022921	benzo(k)fluoranthene	benzo(k)fluoranthene results in increased expression of FGF9 mRNA	19358281
C006780	bisphenol A	bisphenol A results in decreased expression of FGF9 mRNA	27685785
C006780	bisphenol A	bisphenol A results in decreased expression of FGF9 mRNA	22732146
C006780	bisphenol A	bisphenol A results in increased expression of FGF9 mRNA	27022677; 30892605;
C006780	bisphenol A	Fulvestrant inhibits the reaction [bisphenol A results in increased expression of FGF9 mRNA]	30892605
C006780	bisphenol A	bisphenol A results in decreased expression of FGF9 mRNA	25181051
C006780	bisphenol A	bisphenol A results in increased methylation of FGF9 gene	28505145
D003994	Bucladesine	FGF9 protein inhibits the reaction [Bucladesine results in increased abundance of Progesterone]	22872763
D003994	Bucladesine	FGF9 protein inhibits the reaction [IGF1 protein promotes the reaction [Bucladesine results in increased abundance of Androstenedione]]	22872763
D003994	Bucladesine	FGF9 protein inhibits the reaction [IGF1 protein promotes the reaction [Bucladesine results in increased abundance of Progesterone]]	22872763
D003994	Bucladesine	FGF9 protein inhibits the reaction [Bucladesine promotes the reaction [IGF1 protein results in increased abundance of Estradiol]]	22798350
D003994	Bucladesine	FGF9 protein inhibits the reaction [IGF1 protein promotes the reaction [Bucladesine results in increased abundance of Progesterone]]	22798350
D003994	Bucladesine	FGF9 protein promotes the reaction [Bucladesine results in increased abundance of Progesterone]	22798350
C018475	butyraldehyde	butyraldehyde results in increased expression of FGF9 mRNA	26079696
C584509	C646 compound	C646 compound results in increased expression of FGF9 mRNA	26191083
D002101	Cacodylic Acid	Cacodylic Acid results in increased expression of FGF9 mRNA	17720352
D002118	Calcium	Calcium affects the expression of FGF9 mRNA	15913539
D002251	Carbon Tetrachloride	Carbon Tetrachloride results in increased expression of FGF9 protein	17662249
D004390	Chlorpyrifos	Chlorpyrifos results in decreased expression of FGF9 mRNA	20350560
D004390	Chlorpyrifos	Chlorpyrifos affects the expression of FGF9 mRNA	18502319
C074702	chromium hexavalent ion	chromium hexavalent ion affects the expression of FGF9 mRNA	24374135
C031180	chrysene	chrysene results in increased expression of FGF9 mRNA	26377693
D002945	Cisplatin	FGF9 protein affects the susceptibility to Cisplatin	16217747
D005576	Colforsin	FGF9 protein inhibits the reaction [Colforsin promotes the reaction [IGF1 protein results in increased abundance of Estradiol]]	22798350
D005576	Colforsin	FGF9 protein inhibits the reaction [IGF1 protein promotes the reaction [Colforsin results in increased abundance of Progesterone]]	22798350
D000069439	Dasatinib	Dasatinib results in increased expression of FGF9 mRNA	20579391
D016264	Dextran Sulfate	[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of FGF9 mRNA	29950665
D003976	Diazinon	Diazinon affects the expression of FGF9 mRNA	19130878; 22546817;
D003999	Dichloroacetic Acid	Dichloroacetic Acid results in increased expression of FGF9 mRNA	28962523
C036042	dicyclohexyl phthalate	dicyclohexyl phthalate affects the expression of FGF9 mRNA	26924002
D004026	Dieldrin	Dieldrin affects the expression of FGF9 mRNA	22546817
D004026	Dieldrin	Dieldrin results in increased expression of FGF9 mRNA	19130878
D004041	Dietary Fats	Dietary Fats results in increased expression of FGF9 mRNA	30120929
D004051	Diethylhexyl Phthalate	Diethylhexyl Phthalate results in decreased expression of FGF9 protein	27060630
D004051	Diethylhexyl Phthalate	Diethylhexyl Phthalate results in increased expression of FGF9 mRNA	28123099
C024629	dimethyl phthalate	dimethyl phthalate results in decreased expression of FGF9 mRNA	26924002
D004137	Dinitrochlorobenzene	Dinitrochlorobenzene results in increased expression of FGF9 mRNA	20146380
C516138	dorsomorphin	[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FGF9 mRNA	27188386
C516138	dorsomorphin	[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FGF9 mRNA	27188386
C516138	dorsomorphin	[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FGF9 mRNA	27188386
C516138	dorsomorphin	[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FGF9 mRNA	27188386
C516138	dorsomorphin	[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FGF9 mRNA	27188386
C516138	dorsomorphin	[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FGF9 mRNA	27188386
C516138	dorsomorphin	[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FGF9 mRNA	27188386
C516138	dorsomorphin	[NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FGF9 mRNA	27188386
C516138	dorsomorphin	[NOG protein co-treated with Vorinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FGF9 mRNA	27188386
D004317	Doxorubicin	[[MT1 protein co-treated with MT2 protein] affects the susceptibility to Doxorubicin] which affects the expression of FGF9 mRNA	21040762
C118739	entinostat	entinostat results in decreased expression of FGF9 mRNA	26272509; 27188386;
C118739	entinostat	[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FGF9 mRNA	27188386
D004958	Estradiol	Estradiol results in increased expression of FGF9 mRNA	12072406; 14602803; 21098263;
D004958	Estradiol	Estradiol results in increased expression of FGF9 protein	12072406
D004958	Estradiol	[FGF9 protein co-treated with FSHB protein] affects the abundance of Estradiol	22798350
D004958	Estradiol	FGF9 protein inhibits the reaction [Bucladesine promotes the reaction [IGF1 protein results in increased abundance of Estradiol]]	22798350
D004958	Estradiol	FGF9 protein inhibits the reaction [Colforsin promotes the reaction [IGF1 protein results in increased abundance of Estradiol]]	22798350
D004958	Estradiol	FGF9 protein inhibits the reaction [[IGF1 protein co-treated with FSHB protein] results in increased abundance of Estradiol]	22798350
D004958	Estradiol	FGF9 protein inhibits the reaction [IGF1 protein results in increased abundance of Estradiol]	22798350
D004958	Estradiol	[Progesterone co-treated with Estradiol] results in decreased expression of FGF9 mRNA	17404688
D004967	Estrogens	FGF9 protein promotes the reaction [Estrogens results in increased expression of TBX3 protein]	21098263
D004997	Ethinyl Estradiol	Ethinyl Estradiol affects the expression of FGF9 mRNA	16079270
D004997	Ethinyl Estradiol	Ethinyl Estradiol results in decreased expression of FGF9 mRNA	16551644
D004997	Ethinyl Estradiol	Ethinyl Estradiol results in increased expression of FGF9 mRNA	23550701
D000077267	Fulvestrant	Fulvestrant results in decreased expression of FGF9 mRNA	14602803
D000077267	Fulvestrant	Fulvestrant inhibits the reaction [bisphenol A results in increased expression of FGF9 mRNA]	30892605
D005944	Glucosamine	Glucosamine inhibits the reaction [IL1B results in increased expression of FGF9 mRNA]	17109745
D005944	Glucosamine	Glucosamine results in increased expression of FGF9 mRNA	17109745
C492448	ICG 001	ICG 001 results in increased expression of FGF9 mRNA	26191083
D000077146	Irinotecan	Irinotecan analog results in decreased expression of FGF9 mRNA	18927307
C004809	isopentenyl pyrophosphate	isopentenyl pyrophosphate results in increased expression of FGF9 mRNA	14704367
C004809	isopentenyl pyrophosphate	isopentenyl pyrophosphate results in increased expression of FGF9 protein	14704367
C482199	lipopolysaccharide, E coli O55-B5	lipopolysaccharide, E coli O55-B5 results in increased expression of FGF9 protein	23604539
C482199	lipopolysaccharide, E coli O55-B5	neocuproine inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of FGF9 protein]	23604539
C482199	lipopolysaccharide, E coli O55-B5	lipopolysaccharide, E coli O55-B5 results in decreased expression of FGF9 mRNA	19524256
D008070	Lipopolysaccharides	Lipopolysaccharides results in increased expression of FGF9 mRNA	12057914
D008070	Lipopolysaccharides	[Lipopolysaccharides co-treated with Thymic Factor, Circulating co-treated with Zinc] results in increased expression of FGF9 protein	12639846
D008550	Melatonin	Melatonin inhibits the reaction [1-Methyl-4-phenylpyridinium results in decreased expression of FGF9 mRNA]	19476551
D008550	Melatonin	Melatonin inhibits the reaction [1-Methyl-4-phenylpyridinium results in decreased expression of FGF9 protein]	19476551
C042720	mercuric bromide	[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FGF9 mRNA	27188386
C004925	methylmercuric chloride	methylmercuric chloride results in decreased expression of FGF9 mRNA	28001369
C004925	methylmercuric chloride	methylmercuric chloride results in increased expression of FGF9 mRNA	23179753; 27188386;
C517284	monomethyl phthalate	monomethyl phthalate affects the expression of FGF9 mRNA	26924002
D009151	Mustard Gas	IL10 protein affects the reaction [Mustard Gas affects the expression of FGF9 mRNA]	16173061
C560625	N-(2-(3H-indol-3-yl)ethyl)-9-isopropyl-2-(5-methyl-3-pyridyl)purin-6-amine	N-(2-(3H-indol-3-yl)ethyl)-9-isopropyl-2-(5-methyl-3-pyridyl)purin-6-amine inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of FGF9 mRNA]	30203000
C002701	neocuproine	neocuproine inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of FGF9 protein]	23604539
C007350	nitrofen	nitrofen results in decreased expression of FGF9 mRNA	23897418
C007350	nitrofen	nitrofen results in decreased expression of FGF9 protein	23897418
D010126	Ozone	Ozone results in decreased expression of FGF9 mRNA	12763052
D000077767	Panobinostat	[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FGF9 mRNA	27188386
D000077767	Panobinostat	Panobinostat results in decreased expression of FGF9 mRNA	26272509
D052638	Particulate Matter	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Particulate Matter results in increased expression of FGF9 mRNA]	20464547
D052638	Particulate Matter	4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole inhibits the reaction [Particulate Matter results in increased expression of FGF9 mRNA]	20464547
D052638	Particulate Matter	Particulate Matter results in increased expression of FGF9 mRNA	20464547
D052638	Particulate Matter	Particulate Matter results in increased expression of FGF9 protein	20464547
D020245	p-Chloromercuribenzoic Acid	[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FGF9 mRNA	27188386
D020245	p-Chloromercuribenzoic Acid	p-Chloromercuribenzoic Acid results in decreased expression of FGF9 mRNA	26272509
D010662	Phenylmercuric Acetate	[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FGF9 mRNA	27188386
D010662	Phenylmercuric Acetate	Phenylmercuric Acetate results in decreased expression of FGF9 mRNA	26272509
D010672	Phenytoin	Phenytoin results in increased expression of FGF9 mRNA	14741686
D010936	Plant Extracts	Plant Extracts results in increased expression of FGF9 mRNA	21297082
D000072317	Polychlorinated Dibenzodioxins	Polychlorinated Dibenzodioxins results in increased expression of FGF9 mRNA	19358281
D011084	Polycyclic Aromatic Hydrocarbons	Polycyclic Aromatic Hydrocarbons results in increased expression of FGF9 mRNA	16002475; 20464547;
D011084	Polycyclic Aromatic Hydrocarbons	Polycyclic Aromatic Hydrocarbons results in increased expression of FGF9 mRNA	16002475
D011192	Potassium Dichromate	Potassium Dichromate results in decreased expression of FGF9 mRNA	23608068
D011284	Pregnenolone	FGF9 protein inhibits the reaction [[FSHB protein co-treated with IGF1 protein co-treated with trilostane] results in increased abundance of Pregnenolone]	22798350
D011374	Progesterone	FGF9 protein inhibits the reaction [Bucladesine results in increased abundance of Progesterone]	22872763
D011374	Progesterone	FGF9 protein inhibits the reaction [IGF1 protein promotes the reaction [Bucladesine results in increased abundance of Progesterone]]	22872763
D011374	Progesterone	FGF9 protein inhibits the reaction [IGF1 protein results in increased abundance of Progesterone]	22872763
D011374	Progesterone	FGF9 protein inhibits the reaction [[LHB protein co-treated with IGF1 protein] results in increased abundance of Progesterone]	22872763
D011374	Progesterone	FGF9 protein inhibits the reaction [LHB protein results in increased abundance of Progesterone]	22872763
D011374	Progesterone	FGF9 protein results in decreased abundance of Progesterone	22872763
D011374	Progesterone	[FGF9 protein co-treated with FSHB protein] affects the abundance of Progesterone	22798350
D011374	Progesterone	FGF9 protein inhibits the reaction [[IGF1 protein co-treated with FSHB protein] results in increased abundance of Progesterone]	22798350
D011374	Progesterone	FGF9 protein inhibits the reaction [IGF1 protein promotes the reaction [Bucladesine results in increased abundance of Progesterone]]	22798350
D011374	Progesterone	FGF9 protein inhibits the reaction [IGF1 protein promotes the reaction [Colforsin results in increased abundance of Progesterone]]	22798350
D011374	Progesterone	FGF9 protein inhibits the reaction [IGF1 protein results in increased abundance of Progesterone]	22798350
D011374	Progesterone	FGF9 protein promotes the reaction [Bucladesine results in increased abundance of Progesterone]	22798350
D011374	Progesterone	[Progesterone co-treated with Estradiol] results in decreased expression of FGF9 mRNA	17404688
D011374	Progesterone	Progesterone results in decreased expression of FGF9 mRNA	22238285
D011441	Propylthiouracil	Propylthiouracil results in decreased expression of FGF9 mRNA	24780913
C043680	ptaquiloside	ptaquiloside results in decreased expression of FGF9 mRNA	23274088
D020849	Raloxifene Hydrochloride	Raloxifene Hydrochloride affects the expression of FGF9 mRNA	16079270
D012999	Soman	Soman results in increased expression of FGF9 mRNA	19281266
D000077210	Sunitinib	Sunitinib results in increased expression of FGF9 mRNA	31533062
D013629	Tamoxifen	Tamoxifen affects the expression of FGF9 mRNA	24769059
D013749	Tetrachlorodibenzodioxin	N-(2-(3H-indol-3-yl)ethyl)-9-isopropyl-2-(5-methyl-3-pyridyl)purin-6-amine inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of FGF9 mRNA]	30203000
D013749	Tetrachlorodibenzodioxin	Tetrachlorodibenzodioxin affects the expression of FGF9 mRNA	30203000
D013749	Tetrachlorodibenzodioxin	Tetrachlorodibenzodioxin results in increased expression of FGF9 mRNA	19358281; 20106945; 21632981;
D013749	Tetrachlorodibenzodioxin	Tetrachlorodibenzodioxin affects the expression of FGF9 mRNA	26377647
D013749	Tetrachlorodibenzodioxin	[Tetrachlorodibenzodioxin binds to and results in increased activity of AHR protein] which results in decreased expression of FGF9 mRNA	21602191
D013935	Thymic Factor, Circulating	[Lipopolysaccharides co-treated with Thymic Factor, Circulating co-treated with Zinc] results in increased expression of FGF9 protein	12639846
D013974	Thyroxine	Thyroxine results in increased expression of FGF9 mRNA	22798350
C009495	titanium dioxide	[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of FGF9 mRNA	29950665
D014028	Tobacco Smoke Pollution	Tobacco Smoke Pollution results in increased expression of FGF9 mRNA	20464547
D014028	Tobacco Smoke Pollution	[APOE gene mutant form affects the susceptibility to Tobacco Smoke Pollution] which results in increased expression of FGF9 protein	24096154
D014028	Tobacco Smoke Pollution	Tobacco Smoke Pollution deficiency inhibits the reaction [[APOE gene mutant form affects the susceptibility to Tobacco Smoke Pollution] which results in increased expression of FGF9 protein]	24096154
D014028	Tobacco Smoke Pollution	Tobacco Smoke Pollution results in increased expression of FGF9 protein	27793746
C483909	torcetrapib	torcetrapib results in increased expression of FGF9 mRNA	23228038
D014212	Tretinoin	Tretinoin results in increased expression of FGF9 mRNA	21934132
D014212	Tretinoin	Tretinoin results in increased expression of FGF9 mRNA	15621532; 7656983;
C012589	trichostatin A	[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FGF9 mRNA	27188386
C012589	trichostatin A	trichostatin A results in decreased expression of FGF9 mRNA	24935251; 26272509;
C012589	trichostatin A	trichostatin A results in increased expression of FGF9 mRNA	24935251
D014260	Triclosan	Triclosan results in decreased expression of FGF9 mRNA	30510588
D014284	Triiodothyronine	Triiodothyronine promotes the reaction [FGF9 protein results in increased phosphorylation of MAPK1 protein]	16150908
D014284	Triiodothyronine	Triiodothyronine promotes the reaction [FGF9 protein results in increased phosphorylation of MAPK3 protein]	16150908
C009954	trilostane	FGF9 protein inhibits the reaction [[FSHB protein co-treated with IGF1 protein co-treated with trilostane] results in increased abundance of Pregnenolone]	22798350
D014415	Tunicamycin	Tunicamycin results in increased expression of FGF9 mRNA	29453283
D014635	Valproic Acid	[NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FGF9 mRNA	27188386
D014635	Valproic Acid	Valproic Acid results in decreased expression of FGF9 mRNA	23179753; 24383497; 24935251; 26272509; 28001369;
C066075	vanadium pentoxide	vanadium pentoxide results in decreased expression of FGF9 mRNA	17459161
D014640	Vancomycin	Vancomycin results in increased expression of FGF9 mRNA	18930951
C029297	vinylidene chloride	vinylidene chloride results in decreased expression of FGF9 mRNA	26682919
D000077337	Vorinostat	[NOG protein co-treated with Vorinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FGF9 mRNA	27188386
D000077337	Vorinostat	Vorinostat results in decreased expression of FGF9 mRNA	26272509
D015032	Zinc	[Lipopolysaccharides co-treated with Thymic Factor, Circulating co-treated with Zinc] results in increased expression of FGF9 protein	12639846
D000077211	Zoledronic Acid	Zoledronic Acid results in decreased expression of FGF9 mRNA	24714768

Functional annotations

Keywords

Keyword ID	Keyword Term
KW-0002	3D-structure
KW-0209	Deafness
KW-0217	Developmental protein
KW-0221	Differentiation
KW-0903	Direct protein sequencing
KW-0225	Disease mutation
KW-0325	Glycoprotein
KW-0339	Growth factor
KW-0358	Heparin-binding
KW-0497	Mitogen
KW-0621	Polymorphism
KW-1185	Reference proteome
KW-0964	Secreted

Interpro

InterPro ID	InterPro Term
IPR028251	FGF9
IPR002209	Fibroblast_GF_fam
IPR008996	IL1/FGF

PROSITE

PROSITE ID	PROSITE Term
PS00247	HBGF_FGF

Pfam

Pfam ID	Pfam Term
PF00167	FGF

Gene: FGF9

Basic information

Gene expression information

Gene expression in different tissues (GTEx V7)

Gene expression in different tissues (ENCODE)

Protein structural annotations

3D structure in PDB database

Protein disorder information

Orthologous information

Other genetic variants/mutations

Disease or phenotype associated information

Gene Ontology (GO)/biological pathways

GO:Molecular Function

GO:Biological Process

GO:Cellular Component

Reactome Pathway

Drugs and compounds information

Functional annotations

Keywords

Interpro

PROSITE

Pfam

Protein-protein interaction

Protein-miRNA interaction